Stock Analiz

Upstream Bio, Inc. UPB

Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026

$2.78Market cap $152M
Open the interactive analysis →

Upstream Bio, Inc. (UPB) is a healthcare company listed in the US with a market value of about $152M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$164M, a net margin of -5712.3%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -25%.

About Upstream Bio

Upstream Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 4793% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S53.1
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-110.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)20.4%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2846.3%
ROIC (5-yr avg.)-25.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$3M$3M$2M$2M
Net income-$164M-$143M-$63M-$21M
Free cash flow-$168M-$133M-$60M-$38M
EPS (diluted)$-3.01$-2.66$-5.58$-12.95
Net margin-5712.3%-5026.0%-2650.0%-862.9%
ROIC—-37.1%-13.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Upstream Bio pay a dividend?

Not currently.

Is Upstream Bio a good stock to buy?

We do not give buy or sell advice. Upstream Bio scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.